Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial

AIDS

Volumn 16, Issue 5, 2002, Pages 727-736

  Meynard, Jean Luc ^a,d   Vray, Muriel ^a,b,d   Morand Joubert, Laurence ^a,d   Race, Esther ^a,c,d   Descamps, Diane ^a,c,d   Peytavin, Gilles ^a,c,d   Matheron, Sophie ^a,c,d   Lamotte, Claire ^a,c,d   Guiramand, Sonia ^a,d   Costagliola, Dominique ^a,b,d   Brun Vézinet, Francoise ^a,c,d   Clavel, Francois ^a,c,d   Girard, Pierre Marie ^a,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL ROTHSCHILD   (France)

Author keywords

Antiretroviral drugs; Genotype; HIV 1; Phenotype; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG TOLERANCE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; PATIENT COMPLIANCE; PHENOTYPE; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 0037192551     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200203290-00008     Document Type: Article

References (23)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV.1 patients: A prospective cohort study
3. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
4. Incidence and impact of resistance against approved antiretroviral drugs
5. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
6. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
7. HIV-1 genotypic resistance predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
8. Impact of drug resistance mutations on virologic response to salvage therapy
9. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
10. Phenotypic resistance to protease inhibitors in patients who highly active antiretroviral therapy predicts the outcome at weeks twelve of a five-drug combination including ritonavir, saquinavir and efavirenz
11. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
12. Analysis of HIV cross-resistance to protease inhlbitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
13. Phenotypic and genotypic analysis of clinical HIV-1 isolates extensive protease inhibitor cross-resistance: A survey of over 6000 samples
14. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
15. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
16. Phenotypic resistance testing significantly improves response to therapy (Tx): Analysis of a randomized trial (VIRA 30001)
17. A rapid and simple method for extracting human immunodeficiency virus type 1 from plasma: Enhanced sensitivity
18. Transmission of antiretroviral-drug-resistant HIV-1 variants
19. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
20. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
21. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
22. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
23. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy